Why the data on LMIC and EU patient access both point to the same conclusion: the pharmaceutical commercialization playbook needs to be rewritten before leadership of the industry shifts East 1. The LMIC access gap: years, not months A 2024 Health Affairs analysis of IQVIA launch data spanning 1982–2024, covering 119 essential medicines and nearly 6,900 country-level launches across 75 markets, put a hard number on something the industry has long sensed qualitatively: newly available medicines reach different income tiers at radically different speeds. Measured from the date of first global launch, the median time to availability was 2.7 years…
